Polycystic Ovary Syndrome Market, 2021-2031 by Roots Analysis
Polycystic ovary syndrome affects 1 in 10 women of childbearing age. The exact cause of the condition is unknown; however, obesity, high levels of inflammation and insulin resistance are the common risk factors
London
Roots Analysis has announced the
addition of “Polycystic Ovary Syndrome Market, 2021-2031” report to its list of offerings.
Currently, there is no cure for polycystic ovary syndrome
(PCOS / PCOD), however the affiliated symptoms can be treated using a
combination of different types of medications, including insulin-sensitizing
agents, oral contraceptives, anti-androgens and anti-obesity drugs. The
research activities, including clinical investigations in this domain are being
driven by both industry and non-industry players.
To order this 90+ page report, which
features 70+ figures, please visit https://www.rootsanalysis.com/reports/polycystic-ovarian-syndrome-market.html
Key Market Insights
Currently,
more than 60 drugs are marketed / under development for PCOS
More
than 80% of the drugs in the market are designed for symptomatic treatment of
PCOS whilst a few drugs are being evaluated for curing this clinical condition.
Among various types of drugs available, hormonal contraceptives and insulin
sensitizing agents are used for the first line treatment. Popular hormonal
contraceptives include Beyaz®, Clomid®, Diane 35® and Yasmin®.
More than
40 industry and non-industry players are engaged in the development of drugs
for PCOS
Majority
of the industry players (70%) are very large firms (having more than 500
employees). North America is the current hub, where close to 45% players
are based. This is followed by Europe (28%), Asia-Pacific (9%), and Middle East
and North Africa (7%).
Around
700 clinical trials are currently evaluating the therapeutics effects of drugs
for PCOS, worldwide
It is
worth mentioning that more than 50% of the trials were / are being conducted in
Europe and Asia-Pacific region; however, more than 80% of the patients are
enrolled in clinical trials being conducted in North America. Further, 86% of
the total trials are being sponsored by non-industry players.
More than 400 grants have been awarded to support research on
drugs for PCOS, since 2016
An
estimated USD 168.2 million in grants have been awarded to various companies /
organizations working in this domain during the time period between 2016 -April
2021. Almost 60% of the total grant amount was funded by the National Institute
of Child Health and Human Development.
Around 60
eminent scientists (identified as key opinion leaders (KOLs)) are involved in
the clinical trials of drugs for PCOS
More than
30% of these KOLs are associated with the organizations based in Asia-Pacific,
followed by those in Middle East and North Africa (28%), North America (22%)
and Europe (17%). Majority of these KOLs are currently affiliated to schools
and universities.
Close to
3,800 patents have been filed / granted related to PCOS, since 2016
Around
60% of these are patent applications, while rest of the patents have been
granted. Further, R&D activity related to PCOS is largely concentrated in
the US, where over 50% of the total number of patents were filed. Leading
industry players (in terms of the size of intellectual property portfolio)
include Bristol Myers Squibb, Genentech, Merck and Zafgen.
The market is anticipated to grow at a CAGR of 4%, during the
period 2021-2031
Growth in
this domain is anticipated to be driven by the sales of insulin-sensitizing
agents that are expected to capture over 45% of the market share by 2031.
Further, majority share (83%) of the market is captured by oral drugs
To request a sample
copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/polycystic-ovarian-syndrome-market/request-sample.html
Key Questions Answered
§
What are the prevalent R&D trends related to PCOS?
§
What are the key challenges faced by stakeholders in this area?
§
Which are the principal therapies being developed for PCOS?
§
Who are the leading industry and non-industry players in this
field?
§
What are the contributions of big pharma players in this field?
§
Which are the key geographies where research on polycystic
ovarian syndrome is being conducted?
§
Which are the leading administering institute centers supporting
the research in this field?
§
How has the intellectual property landscape in this market
evolved over the years?
§
Who are the key opinion leaders / experts in this field?
§
What are the factors that are likely to influence the evolution
of this market?
§
How is the current and future market opportunity likely to be
distributed across key market segments?
The USD 5
billion (by 2031) financial opportunity within the PCOS market has been
analyzed across the following segments:
§
Drug Class
§
Insulin Sensitizing
Agents
§
Oral Contraceptives
§
Anti-Androgens
§
Anti-Obesity
§
Route of
Administration
§
Oral
§
Subcutaneous
§
Intravenous
§
Others
§
Key Geographical Regions
§
North America (US, Canada)
§
Europe (France, Germany, Italy, Spain, UK)
§
Asia-Pacific and Rest of the World (Australia, China, India
and Japan)
The research includes detailed profiles of key players (listed below), each profile features an
overview of the company, its financial information (if available), drug
portfolio, details on recent developments, as well as an informed future
outlook.
§
AbbVie
§
Bayer
§
GlaxoSmithKline
§
Lupin Pharmaceuticals
§
Merck
§
Pfizer
§
Takeda
§
Teva Pharmaceuticals
For additional details, please visit
https://www.rootsanalysis.com/reports/polycystic-ovarian-syndrome-market.html or
email sales@rootsanalysis.com
You may also be interested in the following titles:
1. Non-hormonal Therapies
for Women’s Health Market, 2021-2030
2.
Squamous Non-Small Cell Lung Cancer: Pipeline Review,
Developer Landscape and Competitive Insights, 2021-2031
3.
Vascular Disrupting Agents Market,
2021-2030
About Roots Analysis
Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots
Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
Comments
Post a Comment